Aktiesnakken — September 2010
-
Our target price of DKr 61 is based upon applying a 25% discount rate to the revenue stream estimates for Arzerra and zalututumumab and
doe -
does not factor in any contribution from the rest of Genmab's pipeline or technology base.
-
hvor er det dog syret at smide 25% discount rate på en fremtidig omsætning man vel reelt set kan betragte som pharma..
-
og ikke biotek
-
nej columbuss, mange fik suppleret meget dyrere
-
amagerbanken over 8
-
den jumper op og ned - det er ren casino. jeg skal ikke nyde noget
-
det er stadig high stakes sorteper indtil de nye aktier kommer i markedet
-
der er præsentationer i london både tirsdag og onsdag. Will we be disappointed?
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind